Key result
Rosuvastatin improved endothelial function, increased systemic NO bioavailability, and inhibited exaggerated platelet activation in rats with experimental congestive heart failure.
Why the study?
Does rosuvastatin improve endothelial function and reduce platelet activation in an experimental rat model of congestive heart failure?
Population
Male Wistar rats with experimental congestive heart failure induced by chronic myocardial infarction via…
Comparison
Rosuvastatin for 10 weeks vs Placebo
Design
Preclinical
Follow-up
10 weeks
Authors
Loading...
No immediate clinical implications in heart failure; hypothesis-generating for statin pleiotropy in experimental models.
Does rosuvastatin improve endothelial function and reduce platelet activation in an experimental rat model of congestive heart failure?
Rosuvastatin improves endothelial function and reduces platelet activation in a rat model of heart failure, highlighting potential pleiotropic mechanisms of statins in this setting.
Schäfer et al. (2005) studied Congestive heart failure (CHF). Rosuvastatin vs. Placebo was evaluated on Endothelial function, NO bioavailability, and platelet activation. Rosuvastatin improved endothelial function, increased systemic NO bioavailability, and inhibited exaggerated platelet activation in rats with experimental congestive heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: